MA49688B1 - Inhibiteur de la télomérase pour la traitement d'un syndrome myélodysplasique - Google Patents
Inhibiteur de la télomérase pour la traitement d'un syndrome myélodysplasiqueInfo
- Publication number
- MA49688B1 MA49688B1 MA49688A MA49688A MA49688B1 MA 49688 B1 MA49688 B1 MA 49688B1 MA 49688 A MA49688 A MA 49688A MA 49688 A MA49688 A MA 49688A MA 49688 B1 MA49688 B1 MA 49688B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- myelodysplastic syndrome
- mds
- telomerase inhibitor
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des procédés de traitement d'un syndrome myélodysplasique (SMD) chez un sujet qui est naïf en termes de traitement avec un agent choisi parmi un agent d'hypométhylation (HMA) et le lénalidomide, ou les deux. Le procédé comprend l'administration au sujet d'une quantité efficace d'un inhibiteur de télomérase, tel que par exemple l'imetelstat ou l'imetelstat sodium. Dans certains cas, le sujet traité est classé comme SMD à risque d'IPSS faible ou intermédiaire 1 et/ou subit une rechute de SMD/est réfractaire à l'agent stimulant l'érythropoïèse (ASE).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538315P | 2017-07-28 | 2017-07-28 | |
| US201762595329P | 2017-12-06 | 2017-12-06 | |
| US201862685542P | 2018-06-15 | 2018-06-15 | |
| PCT/US2018/044225 WO2019023667A1 (fr) | 2017-07-28 | 2018-07-27 | Procédés de traitement du syndrome myélodysplasique |
| EP18755608.9A EP3658156B1 (fr) | 2017-07-28 | 2018-07-27 | Inhibiteur de la télomérase pour la traitement d'un syndrome myélodysplasique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49688A MA49688A (fr) | 2020-06-03 |
| MA49688B1 true MA49688B1 (fr) | 2026-04-30 |
Family
ID=63209674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49688A MA49688B1 (fr) | 2017-07-28 | 2018-07-27 | Inhibiteur de la télomérase pour la traitement d'un syndrome myélodysplasique |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12171778B2 (fr) |
| EP (2) | EP3658156B1 (fr) |
| JP (4) | JP7316261B2 (fr) |
| KR (2) | KR102867725B1 (fr) |
| CN (2) | CN110944646A (fr) |
| AU (2) | AU2018307983B2 (fr) |
| BR (1) | BR112020001749A2 (fr) |
| CA (1) | CA3069010A1 (fr) |
| CL (2) | CL2020000196A1 (fr) |
| DK (1) | DK3658156T3 (fr) |
| ES (1) | ES3073105T3 (fr) |
| FI (1) | FI3658156T3 (fr) |
| HR (1) | HRP20260793T1 (fr) |
| IL (2) | IL324714A (fr) |
| LT (1) | LT3658156T (fr) |
| MA (1) | MA49688B1 (fr) |
| MD (1) | MD3658156T2 (fr) |
| MX (1) | MX2025005894A (fr) |
| NZ (2) | NZ802277A (fr) |
| PL (1) | PL3658156T3 (fr) |
| PT (1) | PT3658156T (fr) |
| RS (1) | RS68210B1 (fr) |
| SG (1) | SG11201913984RA (fr) |
| SI (1) | SI3658156T1 (fr) |
| SM (1) | SMT202600247T1 (fr) |
| TW (2) | TWI906757B (fr) |
| UA (1) | UA127701C2 (fr) |
| WO (1) | WO2019023667A1 (fr) |
| ZA (1) | ZA202000070B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| EP3318276A1 (fr) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques |
| EP3658156B1 (fr) | 2017-07-28 | 2026-03-25 | Geron Corporation | Inhibiteur de la télomérase pour la traitement d'un syndrome myélodysplasique |
| CN113631719A (zh) * | 2018-11-29 | 2021-11-09 | 美国杰龙生物医药公司 | 治疗骨髓增生异常综合征的方法 |
| CA3181682A1 (fr) | 2020-07-17 | 2022-01-20 | Anil Kapur | Compositions inihibitrices de telomerase sous-cutanees et leurs methodes d'utilisation |
| CN116887844A (zh) * | 2021-01-18 | 2023-10-13 | 活跃生物技术有限公司 | 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
| IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| HK1049339B (en) | 1999-09-10 | 2008-06-27 | Geron Corporation | Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use |
| AU2001227965A1 (en) | 2000-01-21 | 2001-07-31 | Geron Corporation | 2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| AU2002245717A1 (en) | 2001-03-23 | 2002-10-08 | Geron Corporation | Oligonucleotide conjugates |
| DK3342425T3 (da) | 2003-09-09 | 2020-03-16 | Geron Corp | Modificerede oligonukleotider til inhibering af telomerase |
| DE602004031975D1 (de) | 2003-11-04 | 2011-05-05 | Geron Corp | Rna-amidate und thioamidateur rnai |
| US20050282893A1 (en) | 2004-01-30 | 2005-12-22 | Au Jessie L | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors |
| RS61840B1 (sr) | 2004-07-02 | 2021-06-30 | Geron Corp | Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera |
| FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| US20060166221A1 (en) | 2005-01-21 | 2006-07-27 | Bahou Wadie F | Methods of diagnosing essential thrombocythemia |
| EP1876893B1 (fr) | 2005-04-15 | 2012-04-11 | Geron Corporation | Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase |
| WO2006113426A2 (fr) | 2005-04-15 | 2006-10-26 | Geron Corporation | Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline |
| TW200730485A (en) | 2005-07-29 | 2007-08-16 | Kalypsys Inc | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| US20070224598A1 (en) | 2006-03-15 | 2007-09-27 | The Methodist Hospital Research Institute | System and method for detection of mutations in JAK2 polynucleotides |
| WO2007127163A2 (fr) | 2006-04-24 | 2007-11-08 | Geron Corporation | Méthode et composition pour le traitement d'une tumeur du snc |
| EP4600359A2 (fr) | 2006-10-30 | 2025-08-13 | Geron Corporation | Inhibiteur de télomérase combiné et gemcitabine pour le traitement du cancer |
| WO2008094640A2 (fr) | 2007-01-30 | 2008-08-07 | Geron Corporation | Composés à effets antiadhésifs sur les cellules cancéreuses |
| ES2407957T3 (es) | 2007-03-09 | 2013-06-17 | Geron Corporation | Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa |
| US8367078B2 (en) | 2007-06-06 | 2013-02-05 | University Of Florida Research Foundation, Inc. | Kinase inhibitor compounds |
| CN101220044B (zh) | 2008-01-21 | 2010-06-02 | 中国药科大学 | 端粒酶抑制剂及其制备方法和用途 |
| US8044240B2 (en) | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
| EP2304436A1 (fr) | 2008-07-10 | 2011-04-06 | Nodality, Inc. | Procédés de diagnostic, pronostic et traitement |
| EP3719139B1 (fr) | 2008-10-17 | 2022-11-30 | Geron Corporation | Procédé d'identification de la sensibilité d'un patient à une thérapie d'inhibition de la télomérase |
| US8772264B2 (en) | 2009-08-04 | 2014-07-08 | Mayo Foundation For Medical Education And Research | Methods of treating hematologic cancers |
| ES2616055T3 (es) | 2010-02-12 | 2017-06-09 | Qiagen Marseille | ASXL1 como nuevo marcador de diagnóstico de neoplasias mieloides |
| WO2012149339A2 (fr) | 2011-04-29 | 2012-11-01 | Sequenom, Inc. | Quantification d'une minorité d'espèces d'acide nucléique |
| US20150005250A1 (en) | 2011-10-13 | 2015-01-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Telomerase reverse transcriptase deficiency as diagnostic marker of myelodysplastic syndrome |
| US20140303191A1 (en) | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| CA2857490C (fr) | 2011-12-22 | 2020-03-31 | Geron Corporation | Analogues de guanine en tant que substrats de telomerase et affecteurs de la longueur de telomeres |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| LT2925889T (lt) | 2012-11-30 | 2018-12-27 | Geron Corporation | Diagnostiniai žymenys, skirti ląstelių prolifreracijos sutrikimų gydymui telomerazės inhibitoriais |
| PT3456333T (pt) | 2012-12-07 | 2020-06-01 | Geron Corp | Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica |
| US9375485B2 (en) * | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| US20150342982A1 (en) * | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
| WO2014160071A1 (fr) | 2013-03-14 | 2014-10-02 | St. Jude Children's Research Hospital | Procédés et compositions pour le traitement de cancers dépendants à la glutamine |
| US11123359B2 (en) | 2013-11-06 | 2021-09-21 | Mayo Foundation For Medical Education And Research | Methods and materials for treating hematological malignancies |
| EP3318276A1 (fr) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques |
| EP3658156B1 (fr) | 2017-07-28 | 2026-03-25 | Geron Corporation | Inhibiteur de la télomérase pour la traitement d'un syndrome myélodysplasique |
-
2018
- 2018-07-27 EP EP18755608.9A patent/EP3658156B1/fr active Active
- 2018-07-27 KR KR1020207003450A patent/KR102867725B1/ko active Active
- 2018-07-27 AU AU2018307983A patent/AU2018307983B2/en active Active
- 2018-07-27 FI FIEP18755608.9T patent/FI3658156T3/fi active
- 2018-07-27 CA CA3069010A patent/CA3069010A1/fr active Pending
- 2018-07-27 TW TW113103931A patent/TWI906757B/zh active
- 2018-07-27 LT LTEPPCT/US2018/044225T patent/LT3658156T/lt unknown
- 2018-07-27 PL PL18755608.9T patent/PL3658156T3/pl unknown
- 2018-07-27 SI SI201831321T patent/SI3658156T1/sl unknown
- 2018-07-27 TW TW107126009A patent/TWI879717B/zh active
- 2018-07-27 IL IL324714A patent/IL324714A/en unknown
- 2018-07-27 JP JP2020504178A patent/JP7316261B2/ja active Active
- 2018-07-27 NZ NZ802277A patent/NZ802277A/en unknown
- 2018-07-27 MD MDE20200587T patent/MD3658156T2/ro unknown
- 2018-07-27 HR HRP20260793TT patent/HRP20260793T1/hr unknown
- 2018-07-27 EP EP26159006.1A patent/EP4763279A3/fr active Pending
- 2018-07-27 WO PCT/US2018/044225 patent/WO2019023667A1/fr not_active Ceased
- 2018-07-27 UA UAA202000156A patent/UA127701C2/uk unknown
- 2018-07-27 DK DK18755608.9T patent/DK3658156T3/da active
- 2018-07-27 PT PT187556089T patent/PT3658156T/pt unknown
- 2018-07-27 US US16/047,502 patent/US12171778B2/en active Active
- 2018-07-27 RS RS20260721A patent/RS68210B1/en unknown
- 2018-07-27 SM SM20260247T patent/SMT202600247T1/it unknown
- 2018-07-27 NZ NZ802272A patent/NZ802272A/en unknown
- 2018-07-27 BR BR112020001749-3A patent/BR112020001749A2/pt not_active Application Discontinuation
- 2018-07-27 CN CN201880049391.2A patent/CN110944646A/zh active Pending
- 2018-07-27 ES ES18755608T patent/ES3073105T3/es active Active
- 2018-07-27 SG SG11201913984RA patent/SG11201913984RA/en unknown
- 2018-07-27 MA MA49688A patent/MA49688B1/fr unknown
- 2018-07-27 CN CN202511334144.5A patent/CN121243203A/zh active Pending
- 2018-07-27 KR KR1020257032602A patent/KR20250151565A/ko active Pending
-
2020
- 2020-01-06 ZA ZA2020/00070A patent/ZA202000070B/en unknown
- 2020-01-21 IL IL272163A patent/IL272163B1/en unknown
- 2020-01-23 CL CL2020000196A patent/CL2020000196A1/es unknown
- 2020-01-24 MX MX2025005894A patent/MX2025005894A/es unknown
-
2021
- 2021-04-28 CL CL2021001096A patent/CL2021001096A1/es unknown
-
2022
- 2022-11-16 JP JP2022183229A patent/JP7654615B2/ja active Active
-
2023
- 2023-11-21 JP JP2023197448A patent/JP7654761B2/ja active Active
-
2024
- 2024-09-20 AU AU2024219941A patent/AU2024219941B2/en active Active
- 2024-11-06 US US18/938,747 patent/US20260115223A1/en active Pending
- 2024-11-12 JP JP2024197684A patent/JP2025013669A/ja active Pending